title: Long-term response to interferon plus ribavirin in patients with chronic hepatitis C refractory to interferon.
abstract: OBJECTIVE
  A sustained response (SR) to interferon (IFN) is only observed in 15-20% of patients with chronic hepatitis C (CHC). The aim of this study was to determine the long-term effectiveness and safety of the treatment with IFN plus ribavirin (RIB) over two years in CHC patients without SR to IFN.
  
  
  METHODS
  A prospective and open longitudinal follow-up study was conducted over 3 years.
  
  
  METHODS
  A total of 77 CHC patients were included: 63 non-responders (NR) and 14 relapsers (R) to IFN. Patients were treated with IFN (3 MU s.c. three times a week) and RIB (1,000-1,200 mg p.o. daily) for 12 months. Treatment tolerance and viral response (HCV-RNA in serum < 1,000 copies/ml) were assessed after 1, 3, 6 and 12 months of treatment. SR and relapsing rates were subsequently evaluated 6, 12 and 24 months after the end of the treatment, together with those variables capable of predicting SR.
  
  
  RESULTS
  At the end of the treatment, 19/77 patients responded (24.7%), 9/63 (14.3%) were non-responders and 10/14 (71.4%) relapsers, and these same patients exhibited SR after 6 months. The SR rate two years after treatment was 22.1% [8/63 (12.7%) NR and 9/14 (64.3%) R]. The relapse rate after 6 months and two years was respectively 0 and 10.5% (2/77). Independent variables capable of predicting SR were negative viremia conversion within the first month of treatment, maintenance of such negative viremia after 6 months, and R status to IFN. Side effects were recorded in 90.9% of cases (70/77), the most frequent being pseudoinfluenza syndrome. Treatment had to be discontinued in 33.8% of patients (26/77).
  
  
  CONCLUSIONS
  Combined IFN-RIB therapy for 12 months in CHC patients without SR to IFN obtains a long-term SR of 22.1%, this rate being higher in relapsers to prior IFN therapy (64.3% in R versus 12.7% in NR).
authors.affiliation: Hepatology Section, Service of Digestive Diseases, Hospital General Universitario, Valencia, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Diago
authors.forename: M
authors.initials: M
authors.lastname: Luján
authors.forename: D
authors.initials: D
authors.lastname: Valeros
authors.forename: C
authors.initials: C
authors.lastname: Tuset
authors.forename: G
authors.initials: G
authors.lastname: Marcaida
authors.forename: V
authors.initials: V
authors.lastname: García
authors.forename: R
authors.initials: R
authors.lastname: Cors
authors.forename: P
authors.initials: P
authors.lastname: Carbonell
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D011446:Prospective Studies; D012254:Ribavirin / Q000627:therapeutic use*; D013997:Time Factors; D017211:Treatment Failure
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin